600 MADISON AVENUE, SUITE 1601, NEW YORK, NY
Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
iBio, Inc. Schedules 2026 Annual Meeting for October 14, 2026
Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
Amended material disclosure
Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
Investor Presentation
Q3
Q2
Amended Quarterly Report
Q1
FY 2025
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
PRE 14A
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence
Submission Upload